| Date Filed | Type | Description |
| 04/26/2021 |
GN
| InnovAge to Announce Third Quarter 2021 Financial Results and Host Conference Call Monday, May 10, 2021 |
| 03/12/2021 |
GN
| InnovAge Announces Exercise of Underwriters' Option to Purchase Additional Shares |
| 02/25/2020 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/25/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/20/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/14/2020 |
8-K
| Quarterly results |
| 02/14/2020 |
8-K
| Quarterly results |
| 01/15/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/13/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 10/03/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/23/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/18/2019 |
8-K
| Acquisition/merger/asset purchase announced |
| 09/18/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/13/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/13/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 08/13/2019 |
8-K
| Quarterly results |
| 07/24/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/22/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/19/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/31/2019 |
8-K
| Investor presentation |
| 05/30/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/15/2019 |
8-K
| Quarterly results|
Docs:
|
"Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 million, a 18.0% Increase From Comparable Quarter in the Prior Year Cash, inclusive of merchant processor holdback, of $2.9 million as of May 13, 2019 SAN DIEGO, May 15, 2019 – Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’ s and women's health and respiratory diseases, announced today its reported results for the three months ended March 31, 2019. Financial highlights for the three months ended March 31, 2019 compared to March 31, 2018 included: ■ Revenues of approximately $5.4 million, an increase of $0.8 million or 18.0% compared to prior year and $0.6 milli..." |
|
| 05/15/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 04/30/2019 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/30/2019 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/11/2019 |
8-K
| Investor presentation |
| 04/01/2019 |
8-K
| Quarterly results |
|